EU application for nimotuzumab for pediatric glioma withdrawn
This article was originally published in Scrip
Oncoscience AG has withdrawn its application to the EMEAfor marketing authorisation of the EGFR-targeted drug nimotuzumab for the treatment of paediatric glioma (brain cancer), saying that it was not able to adequately address the concerns of the CHMP regarding the quality and efficacy of the medicine within the required time schedule.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.